Clinical trials: Human Cancers
Genital Warts
Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response
External genital warts (EGW) are a frequent disease (typical yearly incidence of 100 to 200 new cases per 100.000 person-years, typical prevalence of 1 to 4% of the sexually active population), with a heavy toll on patients'…
- Trial name
- CONDYVAC (NCT03296397)
- Testing
- Vaccination with Gardasil, Injection of Normal Saline
- Where
- 2 sites in France
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HIV Infection, Liver Failure
Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients
This phase I/II, multi-center study is designed to determine the pharmacokinetic profile of Raltegravir in patients with end stage liver disease and to assess drug-drug interaction when Raltegravir is combined with…
- Conditions
- HIV Infection, Liver Failure, Evidence of Liver Transplantation
- Trial name
- LIVERAL (NCT01022476)
- Testing
- Raltegravir potassium
- Where
- France
- Volunteers
- 14 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Advanced Tumors
A Phase I Trial of GW01-200 Tablets in Subjects With Advanced Tumors
A phase 1, open-label, first-in-human study mainly aimed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of GW01-200 tablets in participants with advanced tumors, including solid tumors and…
- Trial name
- GW01-200-01 (NCT07629258)
- Testing
- GW01-200
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Groovy Medicine (Hangzhou) Ltd.
Metastatic Melanoma, Cutaneous Melanoma
Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
This was a Phase 2, open-label study of KW2871 (ecromeximab) in combination with high-dose interferon-α2b (HDI) in patients with metastatic melanoma.
- Trial name
- NCT00679289
- Testing
- HDI, KW2871
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Ludwig Institute for Cancer Research
Graft Versus Host Disease, Hematologic Neoplasms
Optimizing PTCy Dose and Timing
Background: Stem cell or bone marrow transplants can cure or control blood cancers. Sometimes the donor cells see the recipient's body as foreign. This can cause complications.
- Trial name
- NCT03983850
- Testing
- Busulfan, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Plasma Cell Leukemia
To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
This study is a single-arm, open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of human BCMA targeted CAR-NK Cells injection, and to preliminarily observe…
- Trial name
- NCT06045091
- Testing
- Human BCMA targeted CAR-NK cells injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Colorectal Cancer
Diet Modulation of Bacterial Sulfur and Bile Acid Metabolism and Colon Cancer Risk
Determine in the context of a controlled crossover diet-intervention trial the role of taurocholic acid metabolism by gut bacteria in African American subjects at elevated risk for colorectal cancer (CRC).
- Trial name
- NCT03550885
- Testing
- High taurine and saturated fat diet, Low in taurine and saturated fat diet
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Ovarian Cancer, Nonsmall Cell Lung Cancer
First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b
Phase 1b, a study in high grade serous ovarian cancer and nonsmall cell lung cancer to evaluate the safety and clinical activity of the antibody-drug conjugate (ADC) XMT-1592.
- Trial name
- NCT04396340
- Testing
- XMT-1592
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Mersana Therapeutics
Human Papilloma Virus (HPV)
Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease
This study provided data on the performance of the Cobas® 4800 HPV Test for identifying histologically confirmed high-grade cervical disease.
- Trial name
- NCT00709891
- Testing
- cobas® 4800 HPV Test
- Where
- 61 sites in United States
- Volunteers
- 47,208 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Locally Advanced Unresectable or Metastatic Solid Tumors
A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
This is a Phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, and DLTs to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD), and the RP2D of sequential doses of…
- Trial name
- NCT05636215
- Testing
- IBI354
- Where
- 6 sites in Australia, China
- Volunteers
- 368 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Tumors, Medical Oncology
A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4
A study examining the safety of AGS-22M6E or ASG-22CE administered as monotherapy therapy in subjects with malignant solid tumors that express Nectin-4.
- Conditions
- Tumors, Medical Oncology, Neoplasms
- Trial name
- NCT01409135
- Testing
- AGS-22M6E, ASG-22CE
- Where
- 9 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Astellas Pharma Inc
T-Cell Leukemia/Lymphoma, Adult
Novel Therapeutic Approach for Human T-cell Malignancies
This multicenter translational study, with prospective and retrospective samples, aims to identify new strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels.
- Trial name
- NCT06600568
- Testing
- Translation analysis
- Where
- 2 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Lung Cancer, Head and Neck Cancer
A Feasibility Study to Further the Development of Lung Cancer-based Precision Medicine
The purpose of this study is to further advancements in biospecimens (blood cellular free component, e.g., plasma, serum, tissue, urine), in order to develop precision medicine, for lung cancer management and lung cancer…
- Trial name
- NCT02597738
- Testing
- Fresh tissue biopsy, Blood/Urine Sample Collection
- Where
- United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Prostate Neoplasm, Pathology
Impact of Preoperative HbA1c Levels on Pathologic Features and Oncological Outcomes in the Patients With Prostate Cancer
The effect of preoperative glycemic control measured by HbA1c on prostate cancer (PCa) outcome remains controversial. Thus, the investigators aim to examine the association of preoperative glycemic control with oncologic outcomes…
- Trial name
- NCT02436122
- Where
- South Korea
- Volunteers
- 264 people
- Sponsor
- Seoul National University Hospital
Smoldering Multiple Myeloma
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
This study will assess the antimyeloma effects of BHQ880A in patients with smoldering multiple myeloma with high risk of progression to active multiple myeloma.
- Trial name
- NCT01302886
- Testing
- BHQ880
- Where
- 13 sites in United States, France and 1 more
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma
Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma
Intra-lesion administration of an Endothelin Receptor B inhibitor (BQ-788) or vehicle was preformed in 5 melanoma patients to have a preliminary analysis of safety, dose, duration and relevance of results observed in pre-clinical…
- Trial name
- NCT02442466
- Testing
- Endothelin Receptor B inhibitor BQ788, PBS
- Volunteers
- 5 people
- Sponsor
- MelCure SA
Head and Neck Cancer
A Human Versus Machine Comparison Study
The study aims to retrospectively, and anonymously analyse the data of patients treated over a period of 12 months. These are the patients whose radiotherapy plan were needed to be reviewed in the weekly on-treatment head and…
- Trial name
- HuVeM (NCT06035653)
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- East and North Hertfordshire NHS Trust
Pancreatic Cancer Resectable
Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma
Pancreatic adenocarcinoma (PAAD) patients following surgeries are prone to relapse shortly, while it is not well understood by current biomarkers.
- Trial name
- NCT05483257
- Testing
- Multigene panel for next-generation sequencing
- Where
- China
- Volunteers
- 226 people
- Sponsor
- BAIYONG SHEN
High-grade Cervical Intraepithelial Neoplasia, Invasive Cervical Cancer
Randomized Implementation of Primary HPV Testing in the Organized Screening for Cervical Cancer in Stockholm
The purpose is to evaluate whether implementation of primary human papillomavirus (HPV) screening in the screening programme for cervical cancer improves the programme in terms of better cancer protection and better cost…
- Trial name
- NCT01511328
- Testing
- HPV testing
- Where
- Sweden
- Volunteers
- 270,000 people
- Sponsor
- Karolinska Institutet
Human Papillomavirus 18, Cervical Intraepithelial Neoplasia
Human Papillomavirus Epidemiology in Nigeria
Background: Cervical cancer is caused by persistent infection of the lining of the cervix with some kinds of human papillomaviruses (HPV). These HPV infections are distantly related to the viruses that cause warts on the skin.
- Conditions
- Human Papillomavirus 18, Cervical Intraepithelial Neoplasia, Human Papillomavirus 16, Uterine Cervical Neoplasms
- Trial name
- NCT00804466
- Testing
- OncoE6, EVA System
- Where
- Nigeria
- Volunteers
- 1,466 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.